A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation

Background: The epidermal growth factor receptor (EGFR) gene harbors a variety of pathogenic variants in non-small cell lung cancer (NSCLC) with several mutations within exons 18–21 serving as common targets for tyrosine kinase inhibitor (TKI) therapy. Osimertinib is a third generation TKI that was...

Descripció completa

Dades bibliogràfiques

Autors principals:	Daniel J. Craig, Navkirat K. Kahlon, Danae M. Hamouda
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-12-01
Col·lecció:	Current Problems in Cancer: Case Reports
Matèries:	EGFR Tyrosine kinase inhibitors Osimertinib Non-small cell lung cancer
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666621922000527
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!